fbpx

PHYSICIANS

Publications

Rigorous studies, conducted at leading academic medical centers, continue to validate the performance of SelectMDx for Prostate Cancer.

Clinical Validation Study

Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer prior to initial prostate biopsy

Haese A, Trooskens G, Steyaert S, Hessels D, Brawer M, Vlaeminck-Guillem V, Ruffion A, Tilki D, Schalken J, Groskopf J, Van Criekinge W.  Journal of Urology, August 2019.

• N = 1,955 patients

• 95% NPV for GS≥7 prostate cancer

Urinary HOXC6 and DLX1 mRNA levels were quantified and RNA results were then combined with other risk factors in a clinical model optimized to detect Gleason score 7 (Grade Group 2) or greater prostate cancer. SelectMDx demonstrated high sensitivity (93%) and negative predictive value (95%) to detect clinically significant prostate cancer. These data support using the test to help guide initial prostate biopsy decisions.

View All Published Studies

  1. Haese A. et al. (2019) Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer prior to initial prostate biopsy. J Urol. doi: 10.1097/JU.0000000000000293.
  2. Govers TM, et al. (2018) Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment. J Urol. doi: 10.1016/j.juro.2018.07.034.
  3. Govers TM, et al. (2018) Cost-effectiveness of SelectMDx for Prostate Cancer in four European countries: a comparative modeling study. Prostate Cancer and Prostatic Diseases. doi: 10.1038/s41391-018-0076-3.
  4. Trooskens G, et al. (2018) Robust performance of a Urinary Molecular Biomarker-Based Risk Score to detect High-grade Prostate Cancer using optimized cascading models. In: Global Congress on Prostate Cancer; 2018 Jun 28-30; Frankfurt, Germany.
  5. Shore N, et al. (2018) SelectMDx Impacts Prostate Biopsy Decision-making in Routine Clinical Practice. Urology Practice. doi: 10.1016/j.urpr.2018.09.002.
  6. Trooskens G, et al. (2018) Assessment of an established TAUS and a urinary biomarker-based risk score as an inclusion criteria for multiparametric MRI to detect clinically significant prostate cancer. In: Global Congress on Prostate Cancer; 2018 Jun 28-30; Frankfurt, Germany.
  7. Van Neste L, et al. (2016) Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. Eur Ural, Nov; 70(5): 7 40-7 48.
  8. Hendriks RJ, et al. (2017) A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. The Prostate, 77(14):1401-1407.
  9. Hessels D, et al. (2017) Analytical validation of an mRNA-based urine test to predict the presence of high-grade prostate cancer. Translational Medicine Communications, 2:5. doi: 10.1186/ s41231-017-0014-8.
  10. Dijkstra S, et al. (2017) Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics – a decision analytical model. BJU Int, 120(5):659-665. doi: 10.1111 /bju.13861.
  11. Alinezhad S, et al. (2016) Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies. PLoS ONE, 11 (5): e0155go1. doi: 10.1371/journal.pone.0155go1.
  12. Leyten GH, et al. (2015) Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Clin Cancer Res, 21 (13):3061-70.
  13. Vinarskaja A, et al. (2011) DNA Methylation and the HOXC6 Paradox in Prostate Cancer. Cancers, 3:3714-3725. doi: 10.33go/cancers3043714.

Abstracts and Posters

SelectMDx versus Prostate Health Index in the identification of high-grade prostate cancer.

2019 Genitourinary Cancers Symposium

Validation of a two-gene mRNA urine test for detection of high-grade prostate cancer in German men.

2019 Genitourinary Cancers Symposium

Cost-effectiveness of a two-gene urine biomarker assay in MRI strategies for the initial detection of prostate cancer.

2019 Genitourinary Cancers Symposium

SelectMDx versus Prostate Health Index in the identification of high-grade prostate cancer.

2019 Genitourinary Cancers Symposium